Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CCNC | P24863 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1742858 | 1.00 | MAPT (0.39) | MAPTTDP1KAT2BCYP1A2CYP3A4 | |
| SCHEMBL13242139 | 0.82 | KAT2B (0.40) | MAPTKAT2BCYP1A2LMNASMN1; SMN2 | |
| SCHEMBL30148155 | 0.82 | ATR (0.41) | TDP1 | |
| SCHEMBL14153215 | 0.82 | ATR (0.41) | TDP1 | |
| SCHEMBL563457 | 0.78 | ALDH1A1 (0.40) | MAPTTDP1LMNASMN1; SMN2NPC1 | |
| SCHEMBL1743682 | 0.78 | BACE1 (0.38) | CYP1A2SMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL563456 | 0.78 | ALDH1A1 (0.40) | MAPTTDP1LMNASMN1; SMN2NPC1 | |
| SCHEMBL2552457 | 0.77 | ALDH1A1 (0.50) | MAPTTDP1LMNASMN1; SMN2RAB9A | |
| SCHEMBL4001406 | 0.76 | KAT2B (0.38) | MAPTKAT2BLMNASMN1; SMN2NPC1 | |
| SCHEMBL2572082 | 0.76 | HTT (0.50) | MAPTCYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192687-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS INC (US) | 2023-06-22 | — | — | US | disclosed |
| US-11560377-B2 | Fused amino pyridine as HSP90 inhibitors | Guris, Inc. (US) | 2023-01-24 | — | — | US | disclosed |
| US-20210292317-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS INC (US) | 2021-09-23 | — | — | US | disclosed |
| US-10844056-B2 | Fused amino pyridine as HSP90 inhibitors | CURIS, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200062754-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS INC (US) | 2020-02-27 | — | — | US | disclosed |
| US-10428068-B2 | Fused amino pyridine as HSP90 inhibitors | CURIS, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190010152-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS INC (US) | 2019-01-10 | — | — | US | disclosed |
| US-10035797-B2 | Fused amino pyridine as HSP90 inhibitors | CURIS, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20170267674-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS INC (US) | 2017-09-21 | — | — | US | disclosed |
| US-9630965-B2 | Fused amino pyridine as HSP90 inhibitors | CURIS, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-8586605-B2 | Fused amino pyridine as HSP90 inhibitors | CURIS, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2069324-B1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS INC (US) | 2013-07-31 | — | — | EP | disclosed |
| US-8324240-B2 | Fused amino pyridine as HSP90 inhibitors | CURIS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120237508-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS, INC. | 2012-09-20 | — | — | US | disclosed |
| EP-2387316-A1 | FUSED AMINO PYRIDINES FOR THE TREATMENT OF BRAIN TUMORS | Curis, Inc. (US) | 2011-11-23 | — | — | EP | disclosed |
| US-20100184801-A1 | FUSED AMINO PYRIDINES FOR THE TREATMENT OF BRAIN TUMORS | CURIS, INC. | 2010-07-22 | — | — | US | disclosed |
| WO-2010083403-A1 | FUSED AMINO PYRIDINES FOR THE TREATMENT OF BRAIN TUMORS | CURIS, INC. (US) | 2010-07-22 | — | — | WO | disclosed |
| EP-2069324-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | Curis, Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008115719-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS, INC. (US) | 2008-09-25 | — | — | WO | disclosed |
| US-20080234314-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS, INC. | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190010152-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | HSP90B1, HSP90AB1, HSP90AB2P | MAPT 215/4885TDP1 407/4885KAT2B 2914/4885 |
| US-10428068-B2 | Fused amino pyridine as HSP90 inhibitors | HSP90B1, HSP90AB1, HSP90AB2P | MAPT 215/4885TDP1 407/4885KAT2B 2914/4885 |
| US-20170267674-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | HSP90B1, HSP90AB1, HSP90AB2P | MAPT 215/4885TDP1 407/4885KAT2B 2914/4885 |
| US-20120237508-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | HSP90B1, HSP90AB1, HSP90AB2P | MAPT 215/4885TDP1 407/4885KAT2B 2914/4885 |
| US-20230192687-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | HSP90B1, HSP90AB1, HSP90AB2P | MAPT 215/4885TDP1 407/4885KAT2B 2914/4885 |
| US-20080234314-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | HSP90B1, HSP90AB1, HSP90AB2P | MAPT 215/4885TDP1 407/4885KAT2B 2914/4885 |
| US-20100184801-A1 | FUSED AMINO PYRIDINES FOR THE TREATMENT OF BRAIN TUMORS | IDH2, IDH1, AADAT | MAPT 2642/4885TDP1 3112/4885KAT2B 4240/4885 |
| US-20210292317-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | HSP90B1, HSP90AB1, HSP90AB2P | MAPT 215/4885TDP1 407/4885KAT2B 2914/4885 |
| US-20200062754-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | HSP90B1, HSP90AB1, HSP90AB2P | MAPT 215/4885TDP1 407/4885KAT2B 2914/4885 |
| US-11560377-B2 | Fused amino pyridine as HSP90 inhibitors | HSP90B1, HSP90AB1, HSP90AB2P | MAPT 215/4885TDP1 407/4885KAT2B 2914/4885 |
| US-10844056-B2 | Fused amino pyridine as HSP90 inhibitors | HSP90B1, HSP90AB1, HSP90AB2P | MAPT 215/4885TDP1 407/4885KAT2B 2914/4885 |
| US-10035797-B2 | Fused amino pyridine as HSP90 inhibitors | HSP90B1, HSP90AB1, HSP90AB2P | MAPT 215/4885TDP1 407/4885KAT2B 2914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.